Dyslipidemia in renal disease: Causes, consequences and treatment
作者： Joana Mesquita , Ana Varela , José Luís Medina
DOI: 10.1016/J.ENDONU.2010.06.003
关键词:
摘要: The prevalence of chronic renal insufficiency and its complications, including dyslipidemia, is increasing. Although the characteristics dyslipidemia in pathophysiology are well known, cardiovascular impact most effective therapeutic approach poorly defined.
elsevier.es
elsevier.com参考文章(39)
Phillip Bukberg, Ira J. Goldberg, Disorders of Lipoprotein Metabolism Humana Press, Totowa, NJ. pp. 337- 348 ,(2002) , 10.1007/978-1-59259-277-7_19
Grzegorz Piecha, Marcin Adamczak, Eberhard Ritz, Dyslipidemia in chronic kidney disease: pathogenesis and intervention. Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine. ,vol. 119, pp. 487- 492 ,(2009) , 10.20452/PAMW.745
Guido V. Marinetti, Disorders of lipid metabolism Plenum Press. ,(1990) , 10.1007/978-1-4615-9564-9
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. ,vol. 361, pp. 2005- 2016 ,(2003) , 10.1016/S0140-6736(03)13636-7
Jia Liu, Kambiz Kalantarinia, Mitchell H. Rosner, Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease: LIPID MANAGEMENT IN ESRD Seminars in Dialysis. ,vol. 19, pp. 391- 401 ,(2006) , 10.1111/J.1525-139X.2006.00193.X
Nicole M. Isbel, Brian Haluska, David W. Johnson, Elaine Beller, Carmel Hawley, Thomas H. Marwick, Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function American Heart Journal. ,vol. 151, pp. 745- 753 ,(2006) , 10.1016/J.AHJ.2005.06.017
George A. Kaysen, Lipid and Lipoprotein Metabolism in Chronic Kidney Disease Journal of Renal Nutrition. ,vol. 19, pp. 73- 77 ,(2009) , 10.1053/J.JRN.2008.10.011
Tetsuo Shoji, Eiji Ishimura, Masaaki Inaba, Tsutomu Tabata, Yoshiki Nishizawa, Atherogenic lipoproteins in end-stage renal disease American Journal of Kidney Diseases. ,vol. 38, ,(2001) , 10.1053/AJKD.2001.27393
Christoph Wanner, Vera Krane, Uremia-specific alterations in lipid metabolism. Blood Purification. ,vol. 20, pp. 451- 453 ,(2002) , 10.1159/000063557
Daniel M. Levine, Bruce R. Gordon, Lipoprotein(a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications. American Journal of Kidney Diseases. ,vol. 26, pp. 162- 169 ,(1995) , 10.1016/0272-6386(95)90170-1